Capital Fund Management (CFM)
PCRX icon

Capital Fund Management (CFM)’s Pacira BioSciences PCRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,500
Closed -$230K – 1753
2014
Q2 		$230K Buy
+2,500
New +$190K ﹤0.01% 1530

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Capital Fund Management (CFM)'s PCRX Position: Q1 2025 in Review

Capital Fund Management (CFM) sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 175,225 shares — an estimated $3.3M sold.

Capital Fund Management (CFM) first reported a position in PCRX in Q4 2014 and held it in 16 quarters. The position peaked at $7.28M in Q4 2014. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Capital Fund Management (CFM) reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 175,225 Pacira BioSciences shares in Q1 2025, an estimated $3.3M.
  • Capital Fund Management (CFM) first reported a position in Pacira BioSciences in Q4 2014 and held it in 16 quarters.
  • Capital Fund Management (CFM)'s Pacira BioSciences position peaked at $7.28M in Q4 2014.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2025, filed 14 May 2025.